Kara I. Cicero

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano et autres

Functional high-risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12-24 months of front-line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front-line therapies, it is challenging to assign the disease progression to a true …

us, ca (code pays fourni par la source)

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

Raffaella Cassano Cassano, Timothy J. Martins, David Glen Coffey, Gabriele Buda et autres

Abstract Introduction: Relapsed Multiple Myeloma (MM) is a genetically heterogeneous malignancy characterized by variable treatment responses in later lines of therapy. Even with highly effective therapies, most patients will eventually have relapses and require additional treatment options. In this context, precision medicine …

Afrique du Sud, us, it (code pays fourni par la source)

Functional High-Risk (FHR) Phenotype Predicts Poor Survival in Multiple Myeloma (MM) Independent of Frontline Treatment: A Secondary CIBMTR Analysis

Utkarsh Goel, Hossam El‐Sheikh Ali, Saurabh Zanwar, Kara I. Cicero et autres

Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma

Andrew Jay Portuguese, Emily C. Liang, Jennifer J. Huang, Yein Jeon et autres

Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor outcomes following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T therapy, yet its impact on treatment-related toxicity remains unclear. This study evaluates the impact of active EMD on toxicity, efficacy, …

us (code pays fourni par la source)

Corrigendum to Active Extramedullary Disease Predicts ICANS and Early ICAHT after CAR-T Therapy in Multiple Myeloma Transplantation and Cellular Therapy 31/2S (2025) S409

Andrew Jay Portuguese, Emily C. Liang, Jennifer J. Huang, Lorenzo Iovino et autres

us (code pays fourni par la source)

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Rahul Kumar Banerjee, Alicia C. Richards, Shonali Midha, Aimaz Afrough et autres

us, gb (code pays fourni par la source)

Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium

Rahul Banerjee, Alicia C. Richards, Jack Khouri, Murali Janakiram et autres

Introduction The FDA package inserts for both idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM) state that patients should universally refrain from driving for 8 weeks following infusion. However, both ide-cel and cilta-cel use 41BB costimulatory domains with a …

us (code pays fourni par la source)

Active Extramedullary Disease Predicts ICANS and Early ICAHT after CAR-T Therapy in Multiple Myeloma

Andrew Jay Portuguese, Emily C. Liang, Jennifer J. Huang, Lorenzo Iovino et autres

Introduction BCMA-targeted CAR-T therapy has revolutionized treatment for multiple myeloma (MM), showing remarkable efficacy in clinical trials . However, both trial and real-world data indicate that patients (pts) with extramedullary disease (EMD) – whether paraskeletal or true – experience lower response rates …

us (code pays fourni par la source)

High-Intensity Maintenance Post Autologous Stem Cell Transplant Is Independently Associated with Improved Event-Free Survival in Multiple Myeloma

Ivan K. Huang, Grace Baek, Gui Zhen Chen, Omar Marzouk et autres

Following induction therapy, consolidative autologous stem cell transplant (ASCT) and post-transplant maintenance remain a cornerstone for eligible patients with multiple myeloma (MM). Historically, lenalidomide or bortezomib-based monotherapy maintenance has been the standard of care. More aggressive maintenance regimens may be associated with …

us (code pays fourni par la source)

Enhancing Multiple Myeloma Care: Implementation of Pharmacist-Led Prescribing of Immunomodulatory Drugs in an Academic Medical Setting

Amy Indorf, Mary Kwok, Mark Jao, Ashley Chen et autres

Afrique du Sud, us (code pays fourni par la source)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions

Kara I. Cicero, Rahul Kumar Banerjee, Mary Kwok, Danai Dima et autres

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. …

us (code pays fourni par la source)

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Rahul Banerjee, Alicia C. Richards, Jack Khouri, Murali Janakiram et autres

Background: The FDA package inserts for all approved chimeric antigen receptor T-cell (CAR-T) therapies state that patients should universally refrain from driving for 8 weeks following infusion. However, there are no clear data to support this recommendation, particularly in multiple myeloma (MM) …

us (code pays fourni par la source)